# ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

> **NCT00490139** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 8381 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Lapatinib
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT00490139
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05-16
- **Primary completion:** 2013-12-06
- **Final completion:** 2021-07-01
- **Target enrollment:** 8381 (ACTUAL)
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00490139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00490139, "ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00490139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*